164 related articles for article (PubMed ID: 37306107)
21. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Naing A; LoRusso P; Fu S; Hong DS; Anderson P; Benjamin RS; Ludwig J; Chen HX; Doyle LA; Kurzrock R
Clin Cancer Res; 2012 May; 18(9):2625-31. PubMed ID: 22465830
[TBL] [Abstract][Full Text] [Related]
22. Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
Adkins D; Ley J; Neupane P; Worden F; Sacco AG; Palka K; Grilley-Olson JE; Maggiore R; Salama NN; Trinkaus K; Van Tine BA; Steuer CE; Saba NF; Oppelt P
Lancet Oncol; 2019 Sep; 20(9):1295-1305. PubMed ID: 31351869
[TBL] [Abstract][Full Text] [Related]
23. Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA.
Anderson P; Ghisoli M; Crompton BD; Klega KS; Wexler LH; Slotkin EK; Stanbery L; Manning L; Wallraven G; Manley M; Horvath S; Bognar E; Nemunaitis J
Clin Cancer Res; 2023 May; 29(9):1689-1697. PubMed ID: 36780200
[TBL] [Abstract][Full Text] [Related]
24. Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial.
Xu J; Xie L; Sun X; Liu K; Tang X; Yan T; Yang R; Guo W; Gu J
Oncologist; 2021 Jul; 26(7):e1256-e1262. PubMed ID: 33611805
[TBL] [Abstract][Full Text] [Related]
25. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of gemcitabine and nab-paclitaxel in patients with recurrent Ewing sarcoma: A report from the National Pediatric Cancer Foundation.
Oesterheld JE; Reed DR; Setty BA; Isakoff MS; Thompson P; Yin H; Hayashi M; Loeb DM; Smith T; Makanji R; Fridley BL; Wagner LM
Pediatr Blood Cancer; 2020 Jul; 67(7):e28370. PubMed ID: 32386107
[TBL] [Abstract][Full Text] [Related]
27. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
28. Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.
Palmerini E; Jones RL; Setola E; Picci P; Marchesi E; Luksch R; Grignani G; Cesari M; Longhi A; Abate ME; Paioli A; Szucs Z; D'ambrosio L; Scotlandi K; Fagioli F; Asaftei S; Ferrari S
Acta Oncol; 2018 Jul; 57(7):958-964. PubMed ID: 29533113
[TBL] [Abstract][Full Text] [Related]
29. A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
Cash T; Jonus HC; Tsvetkova M; Beumer JH; Sadanand A; Lee JY; Henry CJ; Aguilera D; Harvey RD; Goldsmith KC
Pediatr Blood Cancer; 2023 Aug; 70(8):e30405. PubMed ID: 37158620
[TBL] [Abstract][Full Text] [Related]
30. Impact of Whole Lung Irradiation on Survival Outcome in Patients With Lung Relapsed Ewing Sarcoma.
Scobioala S; Ranft A; Wolters H; Jabar S; Paulussen M; Timmermann B; Juergens H; Hassenpflug W; Klingebiel T; Elsayad K; Eich HT; Dirksen U
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):584-592. PubMed ID: 30244879
[TBL] [Abstract][Full Text] [Related]
31. Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.
Wang BC; Xiao BY; Lin GH
BMC Cancer; 2022 Mar; 22(1):349. PubMed ID: 35361149
[TBL] [Abstract][Full Text] [Related]
32. Oral etoposide in relapsed or refractory Ewing sarcoma: a monoinstitutional experience in children and adolescents.
Podda MG; Luksch R; Puma N; Gandola L; Morosi C; Terenziani M; Ferrari A; Casanova M; Spreafico F; Meazza C; Catania S; Schiavello E; Biassoni V; Chiaravalli S; Massimino M
Tumori; 2016; 102(1):84-8. PubMed ID: 26797935
[TBL] [Abstract][Full Text] [Related]
33. Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1).
Raetz EA; Teachey DT; Minard C; Liu X; Norris RE; Denic KZ; Reid J; Evensen NA; Gore L; Fox E; Loh ML; Weigel BJ; Carroll WL
Pediatr Blood Cancer; 2023 Nov; 70(11):e30609. PubMed ID: 37553297
[TBL] [Abstract][Full Text] [Related]
34. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
[TBL] [Abstract][Full Text] [Related]
35. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.
Schöffski P; Adkins D; Blay JY; Gil T; Elias AD; Rutkowski P; Pennock GK; Youssoufian H; Gelderblom H; Willey R; Grebennik DO
Eur J Cancer; 2013 Oct; 49(15):3219-28. PubMed ID: 23835252
[TBL] [Abstract][Full Text] [Related]
36. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
Olmos D; Postel-Vinay S; Molife LR; Okuno SH; Schuetze SM; Paccagnella ML; Batzel GN; Yin D; Pritchard-Jones K; Judson I; Worden FP; Gualberto A; Scurr M; de Bono JS; Haluska P
Lancet Oncol; 2010 Feb; 11(2):129-35. PubMed ID: 20036194
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.
Van Cutsem E; Eng C; Nowara E; Swieboda-Sadlej A; Tebbutt NC; Mitchell E; Davidenko I; Stephenson J; Elez E; Prenen H; Deng H; Tang R; McCaffery I; Oliner KS; Chen L; Gansert J; Loh E; Smethurst D; Tabernero J
Clin Cancer Res; 2014 Aug; 20(16):4240-50. PubMed ID: 24919569
[TBL] [Abstract][Full Text] [Related]
38. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
[TBL] [Abstract][Full Text] [Related]
39. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Finn RS; Crown JP; Lang I; Boer K; Bondarenko IM; Kulyk SO; Ettl J; Patel R; Pinter T; Schmidt M; Shparyk Y; Thummala AR; Voytko NL; Fowst C; Huang X; Kim ST; Randolph S; Slamon DJ
Lancet Oncol; 2015 Jan; 16(1):25-35. PubMed ID: 25524798
[TBL] [Abstract][Full Text] [Related]
40. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312).
Cole KA; Pal S; Kudgus RA; Ijaz H; Liu X; Minard CG; Pawel BR; Maris JM; Haas-Kogan DA; Voss SD; Berg SL; Reid JM; Fox E; Weigel BJ
Clin Cancer Res; 2020 Mar; 26(6):1213-1219. PubMed ID: 31857431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]